Bailard’s Emergent Biosolutions EBS Stock Holding History

Bailard’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$114K	Hold	13,600	–	–	﹤0.01%	756
2026 Q1	$113K	Buy	+13,600	New	+$141K	﹤0.01%	722

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Bailard's EBS Position: Q2 2026 in Review

Bailard held its Emergent Biosolutions (EBS) position steady in Q2 2026 at 13,600 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #756.

Bailard first reported a position in EBS in Q1 2026 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

Bailard held 13,600 shares of Emergent Biosolutions worth $114K as of Q2 2026.
Bailard left its Emergent Biosolutions share count unchanged in Q2 2026.
Emergent Biosolutions made up ﹤0.01% of Bailard's portfolio in Q2 2026, its #756 holding.
Bailard first reported a position in Emergent Biosolutions in Q1 2026 and has held it in 2 quarters since.
195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.